Insights - Short-sell Tyme Technologies (NASDAQ: TYME) at ~$6 a share Cover (buy-back) this short at <$3 a share by year-end We are short Tyme Technologies (“Tyme”), a $500m+ … Continue Reading
Read NowInsights - Zogenix (ZGNX) will be releasing data from its pivotal Phase 3 program of ‘ZX008’ intended for the treatment of Dravet Syndrome (DS), a form of … Continue Reading
Read NowInsights - We have outlined our reasoning behind certain position changes in our open/closed positions, which can be found on PropThink’s Recent Research page. Bluebird Fairly Valued … Continue Reading
Premium: Read NowInsights - Fennec Pharmaceuticals (FENC:NASDAQ) (FRX.TO:TSX) released the results of its long anticipated Phase 3 study. Interim data showed Fennec’s drug, sodium thiosulfate (“STS”) significantly reduces chemotherapy … Continue Reading
Read NowInsights - After a much-needed meeting between pharmaceutical representatives and Donald Trump this morning, biopharma stocks are rallying. To summarize, Trump’s comments after the meeting (a 10-minute … Continue Reading
Read NowInsights - In case you haven’t already seen the quotes, Donald Trump took aim at the pharmaceutical industry in a press conference this afternoon, sending bio/pharma stocks … Continue Reading
Read NowInsights - U.S. equities continue to sit at all-time highs, with financials, transportation, and energy leading the way, while biotech lags. The under-performance isn’t just from biotech/drug … Continue Reading
Read Now
